

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6694917

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CARSGEN THERAPEUTICS CO., LTD.	01/22/2021
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CAFA THERAPEUTICS LIMITED
<b>Street Address:</b>	2/3 EXCHANGE PLACE, IFSC
<b>City:</b>	DUBLIN
<b>State/Country:</b>	IRELAND
<b>Postal Code:</b>	D01 AE27
<b>PROPERTY NUMBERS Total: 3</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	15746711
Application Number:	15750271
Application Number:	15754076
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(612)455-3801
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6124553800
<b>Email:</b>	ycottle@hsml.com
<b>Correspondent Name:</b>	HAMRE, SCHUMANN, MUELLER & LARSON, P.C.
<b>Address Line 1:</b>	45 SOUTH SEVENTH STREET
<b>Address Line 2:</b>	SUITE 2700
<b>Address Line 4:</b>	MINNEAPOLIS, MINNESOTA 55402-1683
<b>ATTORNEY DOCKET NUMBER:</b>	20352.0145/0146/0147
<b>NAME OF SUBMITTER:</b>	BRYAN A. WONG
<b>SIGNATURE:</b>	/bryan a. wong/
<b>DATE SIGNED:</b>	05/06/2021
<b>Total Attachments: 2</b>	
source=ASSIGNMENT_CAFA#page1.tif	
source=ASSIGNMENT_CAFA#page2.tif	

Attorney Docket Nos.: 20352.0145USWO / 20352.0146USWO / 20352.0147USWO

**ASSIGNMENT**

WHEREAS, **CARSGEN THERAPEUTICS CO., LTD.**, a corporation organized under the laws of China and having an office and place of business at 4th Floor, No. 3 Building No. 466 Yindu Road, Xuhui District, Shanghai 200231 China (hereinafter referred to as the "UNDERSIGNED"), has acquired by assignment inventions for which applications for United States Letters Patent were filed on;

1. January 22, 2018 under Serial No. 15/746711 entitled TUMOR-SPECIFIC ANTI-EGFR ANTIBODY AND APPLICATION THEREOF
2. February 5, 2018 under Serial No. 15/750271 entitled ANTIBODY AGAINST GLYPICAN-3 AND APPLICATION THEREOF
3. February 21, 2018 under Serial No. 15/754076 entitled FULLY HUMAN ANTI-MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN


AND WHEREAS, **CAFA THERAPEUTICS LIMITED**, a corporation organized under the laws of the country of Ireland and having an office and place of business at 2/3 EXCHANGE PLACE, IFSC, DUBLIN, IRELAND D01 AE27, (hereinafter referred to as "ASSIGNEE"), wishes to acquire the right, title and interest in and to said U.S. Letters Patents obtained therefor;

NOW, THEREFORE, for and in consideration of the sum of One Dollar and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the UNDERSIGNED hereby sells, assigns and transfers to the above ASSIGNEE, its successors and assigns, the right, title and interest in the United States in and to U.S. Patent Application Nos. 15/746711, 15/750271 and 15/754076 all reissues or extensions of such patents and the UNDERSIGNED hereby authorizes and requests the Commissioner of Patents to issue any and all United States Letters Patent for the aforesaid invention to the ASSIGNEE of the right, title and interest in and to the same, for the use of the ASSIGNEE, its successors and assigns.

Attorney Docket Nos.: 20352.0145USWO / 20352.0146USWO / 20352.0147USWO

THE UNDERSIGNED represents and agrees with said ASSIGNEE, its successors and assigns, that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been or will be made to others by the UNDERSIGNED, and that full right to convey the same as herein expressed is possessed by the UNDERSIGNED.

IN TESTIMONY WHEREOF, the UNDERSIGNED have hereunto set its hand on the date indicated below.

Date January 22, 2021 Signature:   
Name: Zonghai Li  
Title: CEO  
**CARSGEN THERAPEUTICS CO., LTD.**